Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07422805 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA in Melanoma Patients

Study acronym: ctDNA
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Not applicable to Phase 1/2 Enrollment target: 113 to 176 · Completion pushed from Nov 30, 2023 to Nov 30, 2026 · Trial status: Completed to Active, Not Recruiting · 1 morev3 Show 4 more changesShow less
    • Enrollment target: 113 to 176
    • Completion pushed from Nov 30, 2023 to Nov 30, 2026
    • Trial status: Completed to Active, Not Recruiting
    • Study description shortened, about 29 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study Status, Eligibilityv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study evaluates the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.
Trial Details
NCT Number NCT07422805
Lead Sponsor Institute of Oncology Ljubljana
Conditions Melanoma, Skin Cancer
Enrollment 176 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov